Tecan’s multimode readers offer staying power for biomolecular research
7 February 2013 | By kdm communications limited
Scientists at the University of Toronto, Canada, have chosen generations of Tecan microplate readers to monitor...
List view / Grid view
7 February 2013 | By kdm communications limited
Scientists at the University of Toronto, Canada, have chosen generations of Tecan microplate readers to monitor...
7 February 2013 | By Amgen
Amgen outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City...
7 February 2013 | By GlaxoSmithKline
GSK announced submission of a Marketing Authorisation Application...
6 February 2013 | By Biogen Idec
Biogen Idec has agreed to purchase Elan’s interest in TYSABRI...
5 February 2013 | By kdm communications limited
Avacta Analytical has unveiled the Optim® 2 micro-volume protein analysis and characterisation instrument...
AbbVie has announced the European Commission (EC) has approved an update to the label for HUMIRA® (adalimumab) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). The update adds data demonstrating the long-term clinical benefit of HUMIRA, making it the first and only biologic medication available with…
5 February 2013 | By Sanofi
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen...
5 February 2013 | By GlaxoSmithKline
“We are very pleased with the outcome of this transaction..."
4 February 2013 | By Gilead Sciences, Inc.
Topline results from two Phase 3 studies...
4 February 2013 | By Sanofi
Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist...
4 February 2013 | By B&W Tek, Inc.
B&W Tek is proud to announce the i-Raman® Plus portable Raman spectrometer...
1 February 2013 | By GlaxoSmithKline
GSK announced the start of COMBI-AD...
31 January 2013 | By Roche
Positive results from stage 1 of CLL11...
31 January 2013 | By BASF
BASF has completed the acquisition of Pronova BioPharma ASA, Lysaker, Norway...
31 January 2013 | By Novo Nordisk
Sales growth of 18% driven by Victoza®, NovoRapid® and Levemir®...